Dark

RXST
RxSight, Inc. Common Stock
stock NASDAQ

At Close

Jul 6, 2026 3:59:56 PM EDT

5.62USD+0.178%(+0.01)1,065,579

4.80Bid 6.82Ask 2.02Spread

Pre-market

Jul 6, 2026 8:37:30 AM EDT

5.61USD0.000%(0.00)500

After-hours

Jul 6, 2026 4:49:30 PM EDT

4.90USD-12.811%(-0.72)45,500

OverviewOptionsHistoricalExchangesShortsNews

Jan 10, 2022

02:31PM EST Mid-Afternoon Market Update: Dow Tumbles 250 Points; Zynga Shares Spike Higher Benzinga

Jan 9, 2022

04:55PM EST RxSight Sees Q4 Revenue ~$8.4M vs $7.07M Est; Sees FY 2022 Revenue ~$22.6M vs $21.23M Est Benzinga

04:00PM EST (NASDAQ: RXST) RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today announced preliminary unaudited financial and operational results for the fourth quarter and fiscal year 2021. GlobeNewswire Inc

Jan 4, 2022

04:05PM EST (NASDAQ: RXST)RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today announced the appointment of Tamara R. Fountain, M.D. and Shweta Singh Maniar to its Board of Directors. GlobeNewswire Inc

Dec 28, 2021

04:05PM EST RxSight, Inc. (NASDAQ: RXST), an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today announced plans to participate in the upcoming virtual J.P. Morgan Healthcare Conference. GlobeNewswire Inc

Nov 18, 2021

04:05PM EST (NASDAQ: RXST)RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today announced plans to participate in the upcoming virtual Ophthalmology Day at BTIG. GlobeNewswire Inc

Nov 10, 2021

05:44PM EST RxSight Sees FY21 Sales $21.0M-$21.4M Vs. $20.77M Est. Benzinga

05:42PM EST RxSight Q3 EPS $(0.65) Misses $(0.62) Estimate, Sales $5.79M Beat $5.22M Estimate Benzinga

04:09AM EST Earnings Scheduled For November 10, 2021 Benzinga

Oct 27, 2021

04:05PM EDT RxSight, Inc., an ophthalmic medical device company, today announced that it will report financial results for the third quarter of 2021 after the market close on Wednesday, November 10, 2021. The companys management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. GlobeNewswire Inc

Sep 9, 2021

04:05PM EDT RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today reported financial results for the three months ended June 30, 2021. GlobeNewswire Inc

Sep 1, 2021

08:00AM EDT RxSight Announces Updated Date for Reporting Second Quarter 2021 GlobeNewswire Inc

Aug 31, 2021

08:00AM EDT RxSight, Inc. (NASDAQ: RXST), an ophthalmic medical device company, today announced plans to participate in the upcoming virtual Wells Fargo Healthcare Conference. GlobeNewswire Inc

Aug 24, 2021

04:05PM EDT RxSight, Inc., an ophthalmic medical device company, today announced that it will report financial results for the second quarter of 2021 after the market close on Tuesday, September 7, 2021. The companys management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. GlobeNewswire Inc

10:03AM EDT Benzinga's Top Ratings Upgrades, Downgrades For August 24, 2021 Benzinga

08:23AM EDT JP Morgan Initiates Coverage On RxSight with Overweight Rating, Announces Price Target of $16 Benzinga

07:31AM EDT B of A Securities Initiates Coverage On RxSight with Buy Rating, Announces Price Target of $17 Benzinga

07:21AM EDT BTIG Initiates Coverage On RxSight with Buy Rating, Announces Price Target of $28 Benzinga

07:15AM EDT Wells Fargo Initiates Coverage On RxSight with Overweight Rating, Announces Price Target of $20 Benzinga

06:15AM EDT SVB Leerink Initiates Coverage On RxSight with Outperform Rating, Announces Price Target of $20 Benzinga

Aug 20, 2021

07:45AM EDT The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data Benzinga

Aug 18, 2021

07:38AM EDT The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline Benzinga

Aug 17, 2021

04:05PM EDT (NASDAQ: RXST) RxSight, Inc., an ophthalmic medical device company, today announced that Steve Everly has joined the company as its Vice President of U.S. Sales. In this new position, Mr. Everly will lead the continued development and expansion of the companys sales organization. GlobeNewswire Inc

Aug 11, 2021

09:31AM EDT Cramer Gives His Opinion On Skyworks Solutions, Paysafe And More Benzinga

08:14AM EDT The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering Benzinga

Aug 6, 2021

07:42AM EDT The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO Benzinga

Aug 5, 2021

08:08AM EDT The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO Benzinga

Aug 4, 2021

04:05PM EDT RxSight, Inc. Announces Closing of Initial Public Offering and GlobeNewswire Inc

Jul 30, 2021

11:23AM EDT RxSight Shares Open For Trade At $17.50; IPO Priced At $16/Share Benzinga

09:19AM EDT RxSight Shares Will Open For Quote At 10:10 a.m. EDT, Expected To Open For Trade After 10:20 a.m. EDT; IPO Priced At $16/Share Benzinga

07:54AM EDT The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs Benzinga

.dark-mode .lH0RLJ{ color: white; background-color: #333333; border: 2px solid white; }.light-mode .lH0RLJ{ color: #333333; background-color: white; border: 2px solid #333333; }RXSTRxSight, Inc. Common Stockstock NASDAQ

RXST
RxSight, Inc. Common Stock
stock NASDAQ